Avai Bio (AVAI) Liabilities and Shareholders Equity (2018 - 2026)

Avai Bio has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $791750.0 for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 444.88% year-over-year to $791750.0; the TTM figure through Jun 2026 stood at $1.8 million (up 143.64% YoY), while the FY2026 annual figure was $572696.0, up 154.82% from the prior year.
• Liabilities and Shareholders Equity came in at $791750.0 for Q2 2026 at Avai Bio, up from $572696.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $791750.0 in Q2 2026 to a low of $145306.0 in Q2 2025.
• Average Liabilities and Shareholders Equity over 5 years is $311157.0, with a median of $269740.0 recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity slumped 55.41% in 2022 and surged 444.88% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $284890.0 in 2022, then grew by 2.23% to $291246.0 in 2023, then tumbled by 39.95% to $174886.0 in 2024, then retreated by 1.13% to $172912.0 in 2025, then surged by 357.89% to $791750.0 in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $791750.0 in Q2 2026, $572696.0 in Q1 2026, and $172912.0 in Q4 2025.